Tech Company Financing Transactions
DiscGenics Funding Round
DiscGenics secured a $50 million Series C venture capital round on 8/31/2020. Investors included CIZ Holdings, CareNet and Eagle Fund SP1.
Transaction Overview
Company Name
Announced On
8/31/2020
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Proceeds Purpose
The company will use the new capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease (DDD), to fund future commercialization activities in the U.S. and Japan, and for the scale up and scale out of its allogeneic cell manufacturing facility in Salt Lake City, UT.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5940 W Harold Gatty Dr. 106
Salt Lake City, UT 84116
USA
Salt Lake City, UT 84116
USA
Phone
Website
Email Address
Overview
We are a biotechnology company developing advanced spinal stem cell therapeutics to treat patients with diseases of the intervertebral disc.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Flagg Flanagan
Chief Medical Officer
Kevin Foley
Chief Operating Officer
Bob Wynalek
Browse more venture capital transactions:
Prev: 8/31/2020: LaunchNotes venture capital transaction
Next: 8/31/2020: Raptor Maps venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs